As for T2D treatment, the majority (87%) of patients were on metformin, 12.5% on acarbose, 29.8% on secretagogues, 23.1% on DPP-4 inhibitors (DPP-4i) and 2.9% on pioglitazone, without any gender differences. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.